An article published by Niikura et al. in 2012 showed that in 182 patients with HER-2-positive primary breast cancer and systemic metastases, the HER-2 inconsistency was significantly associated with poorer survival (27), however, the paper published by Amir et al. reported that the HER-2 inconsistency had no deleterious effect on the overall survival of patients (12). The gene discussed is ERBB2; the disease is breast cancer.